Kocaeli City Hospital
Kocaeli, Izmit, Turkey (Türkiye)
NCT Number: NCT07734480
This prospective observational study aims to objectively measure the lead-time (the time from the first KDS alert to sepsis diagnosis) of the NEWS2-based clinical decision support system (KDS) and compare its early warning performance with a machine learning model trained on 2000 patients and externally validated. The study seeks to answer the following main questions:
How early does the NEWS2-based KDS provide an alert before sepsis diagnosis?
Does a machine learning model, developed using logistic regression and externally validated in a prospective cohort, offer superior specificity and comparable sensitivity to KDS?
Participants who are already receiving routine clinical care at Kocaeli City Hospital will have their vital signs and laboratory data monitored as part of standard practice. NEWS2 scores will be calculated automatically and the time of the first alert (T0) will be recorded. Sepsis diagnosis will be confirmed by an increase in SOFA score ≥ 2 (T1), evaluated by two independent and blinded physicians. Lead-time will be calculated as the difference between T1 (hours×60) and T0 (minutes). The machine learning model will be tested prospectively on this cohort, and its performance will be compared with KDS using sensitivity, specificity, F1 score, ROC-AUC, and accuracy.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Kocaeli, Izmit, Turkey (Türkiye)
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Early recognition and treatment are critical for improving outcomes. The National Early Warning Score 2 (NEWS2) is widely used as an early warning system, but its lead-time (the time from alert to diagnosis) has not been objectively measured in prospective studies. This study aims to fill this gap by prospectively evaluating the lead-time of NEWS2-based KDS and comparing its performance with a machine learning model. The machine learning model was developed using 2000 patients from the PhysioNet Sepsis Prediction Challenge 2019 database and externally validated on a prospective cohort of 100 patients from Kocaeli City Hospital. The study will provide evidence on the comparative utility of traditional warning systems and machine learning approaches for early sepsis detection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational Study - No Intervention
Time frame: From hospital admission to sepsis diagnosis, death, or discharge, whichever occurs first, assessed up to 14 days
Lead-time is defined as the time from the first KDS alert (NEWS2 ≥ 5) to the diagnosis of sepsis, confirmed by an increase in SOFA score ≥ 2 points. It is calculated using the formula: Lead-Time (minutes) = [T1 (hours × 60)] - T0 (minutes), where T0 is the time of the first NEWS2 measurement and T1 is the time of first SOFA increase ≥ 2.
Time frame: Within 14 days of hospital admission
Kocaeli Derince Education and Research Hospital
Other
Comparison of NEWS2 and a Machine Learning Model for Early Sepsis Warning: A Prospective Observational Study
Acronym: SEW-ML
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06817408
Infections, Inflammation
Rochester, Minnesota, United States
View Trial DetailsNCT04796285
Communicable Diseases, Disease Attributes
Boston, Massachusetts, United States
View Trial DetailsNCT06765681
Blood Coagulation Disorders, Cardiovascular Diseases
Whippany, New Jersey, United States
View Trial DetailsNCT05671159
Infections, Inflammation
Limoges, France
View Trial Details